Cognitive-metabolic relationship in temporal lobe epilepsy: A systematic review.

Epilepsy BehavAug 3, 2026 (epub)
Clinical ResearchNeurology

Mathias Maisenbacher, Ola Alshaqi, Xiaohan Peng et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined the relationship between neurometabolic dysfunction and cognitive impairment in 1161 patients with temporal lobe epilepsy (TLE). The analysis of 38 studies revealed that verbal memory impairment is consistently linked to left temporal lobe metabolic changes, particularly through 18F-FDG PET imaging. The findings underscore the multifaceted nature of cognitive decline in TLE.

Key findings

  • Verbal memory impairment is consistently associated with left temporal lobe metabolite changes.
  • Non-memory cognitive impairments correlate with changes in glucose metabolism and specific brain metabolites.
  • 18F-FDG PET is the most commonly used imaging modality for assessing cognitive-metabolic correlates in TLE.

Why it matters

Understanding the cognitive-metabolic relationship in TLE can help identify potential biomarkers for cognitive decline, guiding future therapeutic strategies and improving patient management.

Source

PubMed · PMID 42546587

Published in Epilepsy Behav. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.